or Try an Advanced Search...

    Technical Analysis for ARVN - Arvinas, Inc.

    Grade Last Price % Change Price Change
    D 29.65 0.44% 0.13
    ARVN closed up 0.44 percent on Friday, July 26, 2024, on 44 percent of normal volume.
    Earnings due: Aug 6
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Up Down
    Historical ARVN trend table...
    Date Alert Name Type % Chg
    Multiple of Ten Bearish Other 0.00%
    Wide Bands Range Expansion 0.00%
    Gapped Up Strength 0.00%
    Multiple of Ten Bearish Other 0.44%
    Inside Day Range Contraction 0.44%
    Wide Bands Range Expansion 0.44%
    50 DMA Support Bullish 2.70%
    Multiple of Ten Bearish Other 2.70%
    Wide Bands Range Expansion 2.70%
    50 DMA Support Bullish -1.17%
    Older End-of-Day Signals for ARVN ...

       Recent Intraday Alerts

    Alert Time
    Down 1% about 6 hours ago
    60 Minute Opening Range Breakdown about 10 hours ago
    10 DMA Support about 11 hours ago
    10 DMA Resistance about 11 hours ago
    Rose Above Previous Day's High about 11 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    ARVN Chart by TradingView
    Basic chart:

    Profile

    Arvinas Inc. is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Arvinas uses its proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC™ protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Biology Disease Genetics Metabolism Chimera

    Is ARVN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jul 22 HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
    Jul 17 Biotech Arvinas Stock Earns 82 RS Rating
    Jul 17 Arvinas (ARVN) Surges 9.2%: Is This an Indication of Further Gains?
    Jul 16 UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday
    Jul 15 Milestone Pharmaceuticals Refreshes Board of Directors
    Jul 12 Arvinas: Hugely Important Data Catalyst Upcoming - Success May Prove Elusive
    Jun 27 Arvinas, Inc. (ARVN): Why Did Analysts Give This Small-Cap Stock a Strong Buy Rating?
    Jun 24 Arvinas appoints Andrew Saik as CFO
    Jun 24 Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer
    Jun 24 Cytek Biosciences (CTKB) Moves 5.1% Higher: Will This Strength Last?
    See more ARVN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 53.08
    52 Week Low 13.57
    Average Volume 890,607
    200-Day Moving Average 32.83
    50-Day Moving Average 28.79
    20-Day Moving Average 28.03
    10-Day Moving Average 29.83
    Average True Range 1.68
    RSI (14) 54.75
    ADX 21.94
    +DI 26.57
    -DI 17.12
    Chandelier Exit (Long, 3 ATRs) 29.06
    Chandelier Exit (Short, 3 ATRs) 28.44
    Upper Bollinger Bands 32.56
    Lower Bollinger Band 23.51
    Percent B (%b) 0.68
    BandWidth 32.27
    MACD Line 0.53
    MACD Signal Line 0.30
    MACD Histogram 0.2352
    Fundamentals Value
    Market Cap 1.63 Billion
    Num Shares 55 Million
    EPS -5.52
    Price-to-Earnings (P/E) Ratio -5.37
    Price-to-Sales 17.22
    Price-to-Book 6.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 31.20
    Resistance 3 (R3) 31.22 30.73 30.94
    Resistance 2 (R2) 30.73 30.34 30.72 30.85
    Resistance 1 (R1) 30.19 30.09 29.95 30.17 30.77
    Pivot Point 29.70 29.70 29.58 29.69 29.70
    Support 1 (S1) 29.16 29.31 28.92 29.14 28.53
    Support 2 (S2) 28.67 29.06 28.66 28.45
    Support 3 (S3) 28.13 28.67 28.36
    Support 4 (S4) 28.11